Nov 7 (Reuters) – Evaxion A/S: * NEW PHASE 2 DATA HIGHLIGHT THE STRENGTH OF THE IMMUNE RESPONSE INDUCED BY PERSONALIZED CANCER VACCINE EVX-01 * EVAXION A/S – DATA HIGHLIGHTS STRONG PREDICTIVE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)